Second Sight Medical Products (EYES) Lowered to “Sell” at ValuEngine

Second Sight Medical Products (NASDAQ:EYES) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday, ValuEngine reports.

Shares of NASDAQ EYES opened at $0.96 on Tuesday. Second Sight Medical Products has a fifty-two week low of $0.63 and a fifty-two week high of $2.25. The stock has a market cap of $127.77 million, a P/E ratio of -1.85 and a beta of 2.30.

Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings data on Wednesday, March 13th. The medical device company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). Second Sight Medical Products had a negative net margin of 508.90% and a negative return on equity of 809.08%. The business had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $2.60 million. On average, research analysts predict that Second Sight Medical Products will post -0.28 EPS for the current year.

An institutional investor recently bought a new position in Second Sight Medical Products stock. Wiley BROS. Aintree Capital LLC acquired a new stake in shares of Second Sight Medical Products Inc (NASDAQ:EYES) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 51,961 shares of the medical device company’s stock, valued at approximately $41,000. Institutional investors and hedge funds own 6.18% of the company’s stock.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma.

Featured Story: What defines an oversold asset?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.